Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » Lutate access in NSW

Home » Advocacy » Lutate access in NSW

Lutate access in NSW

  • May 4, 2015
For the last 5 years, the Unicorn Foundation working with the NSW Agency for Clinical Innovation, has developed and promoted a clinical pathway for the provision of Lutate in NSW hospitals.

As of January 2015 the NSW Ministry of health is supporting an evaluation of Lutate therapy at two sites – St George and Royal North Shore Hospitals. NET patients in NSW, if they are to be considered as potential recipients by their treating doctor of this therapy, need to be referred to and assessed by the NET MDT at either one (St George or Royal North Shore Hospitals) of the two NSW Lutate Services .

 

When patients are referred to one of the two NSW Lutate Services, they will be added to a NETs MDT Register and depending on availability, access and capacity of each centre, may be treated at either institution, rather than the most geographically convenient. Patients will also need to meet nationally agreed patient selection criteria before Lutate treatment can be considered.

 

For more information go to http://www.aci.health.nsw.gov.au/networks/nuclear-medicine/resources or print the referral protocol from the Unicorn Foundation (download below). It is important for all NSW NET patients to inform their treating doctors of this service to ensure that they are receiving the best possible care and clinical outcomes for the management of their NET.

https://neuroendocrine.org.au/wp-content/uploads/2020/03/NM-Lutate-referral-and-protocol_2015_01_12.pdf

Share this post

Recent posts

13th INCA Global NET Patient Advocate Summit

September 16, 2025

PCPA Cancer Summit

September 12, 2025

SCAN 2025 is now open – we need your voice

September 8, 2025

NeuroEndocrine Cancer Australia at PharmaAus2025

September 3, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousSenate Inquiry – Availability of new, innovative and specialist cancer drugs in Australia
NextNET Nurse Petition UpdateNext

Related Posts

PCPA Cancer Summit

  The Private Cancer Physicians of Australia (PCPA) hosted its Annual Meeting: Cancer Summit 2025 in Sydney on 13 September, bringing together clinicians, researchers, and

SCAN 2025 is now open – we need your voice

SCAN 2025 is now open – we need your voice.  As a proud member of the International Neuroendocrine Cancer Alliance (INCA), NeuroEndocrine Cancer Australia is excited

Medicines Australia Horizon Scanning – Advancing Patient Access and Genomics

NeuroEndocrine Cancer Australia CEO Meredith Cummins joined a panel discussion at the Medicines Australia Horizon Scanning event, accompanied by Media and External Relations Manager Ciara

CanForum 2025: Now it’s personal: Access and equity for all

On 2nd September 2025, NeuroEndocrine Cancer Australia CEO Meredith Cummins and Media and External Relations Manager Ciara Connolly attended CanForum 2025, a leading national conference

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin